Drugs / EBV Specific T-Lymphocytes
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT04364178 | Aug 2020 → Feb 2023 | Epstein-Barr virus infection, adenoviridae infectious disease, cytomegalovirus infection | Jessie L. Alexander, MD | Terminated | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | EBV Specific T-Lymphocytes | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04364178 ↗ |
| Modality | Cell therapy | “viral specific T cells” NCT04364178 ↗ |